GlassScriptPhysician profile
Priscilla Ortega
NPI 1598834889
$7,512.87
in general payments reported to CMS, 2019-2025
29 companies · $1,810 in 2025
The $1,810 reported for 2025 was more than what 90% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $835 · 2022: $980 · 2023: $1,667 · 2024: $2,221 · 2025: $1,810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,697.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,721.73 | 2021-2025 | Briviact, Fintepla, Nayzilam |
| Neurelis, INC. | $1,572.79 | 2021-2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $718.29 | 2023-2025 | |
| Corium, LLC | $357.06 | 2023-2025 | Azstarys |
| Sumitomo Pharma America, INC. | $352.92 | 2023-2024 | Aptiom |
| Eisai INC. | $312.39 | 2021-2022 | |
| Otter Pharmaceuticals, LLC | $272.47 | 2024-2025 | Sympazan |
| Zogenix INC. | $164.56 | 2021 | |
| Supernus Pharmaceuticals, INC. | $163.11 | 2021-2024 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $162.15 | 2021-2022 | |
| Sk Life Science, INC. | $152.66 | 2023-2025 | |
| Collegium Pharmaceutical, INC. | $70.70 | 2025 | Jornay Pm |
| Greenwich Biosciences, INC. | $56.29 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.59 | 2021-2022 | |
| Immedica Pharma US, INC. | $45.51 | 2022-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $42.68 | 2025 | Daybue |
| Xeris Pharmaceuticals, INC. | $38.74 | 2021-2024 | Keveyis |
| Itf Therapeutics LLC | $33.80 | 2025 | |
| Livanova USA, INC. | $33.31 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Inspire Medical Systems, INC. | $26.39 | 2025 | Inspire |
| Pyros Pharmaceuticals, INC. | $23.19 | 2024 | Vigpoder |
| Genzyme Corporation | $23.01 | 2023 | |
| Catalyst Pharmaceuticals, INC. | $21.90 | 2024 | |
| Genentech USA, INC. | $20.69 | 2022 | |
| Lilly USA, LLC | $19.91 | 2025 | Zepbound |
| Sarepta Therapeutics, INC. | $18.47 | 2024 | Exondys 51 |
| Ironshore Pharmaceuticals INC. | $15.06 | 2024 | |
| Biomarin Pharmaceutical INC. | $13.86 | 2021 | |
| Tris Pharma INC | $13.64 | 2025 | Onyda Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priscilla Ortega listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.